The globalization of US medical countermeasure production and its implications for national security

Amesh A. Adalja, Samuel B. Wollner, Thomas V. Inglesby, George Poste

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Recent cases of counterfeit and contaminated medications have raised concerns about the integrity of the US supply chain of pharmaceuticals. Moreover, shortages in oncology drugs have highlighted a weak domestic production capacity for essential medications. The FDA and the Pew Charitable Trusts have published analyses of the problems as they relate to the US's regulatory system and healthcare industry.1,2 These issues also represent a potential national security threat. In preparing for and responding to pandemic influenza, US officials realized that a lack of domestic production capacity for flu vaccines and therapeutics heightened political tensions and shook popular confidence when these products became scarce. In 2005, Roche struggled to meet demand for oseltamivir because of a bad harvest of the star anise plant. Star anise is the source of shikimic acid, the backbone of the medication, and grows almost exclusively in 5 provinces of China. As a buffer against future shortages, 50 million doses were acquired for the Strategic National Stockpile (SNS), the federal repository of medical countermeasures (MCMs), to be used in a national emergency. In 2011, to augment domestic influenza vaccine production capacity, Novartis opened the first cell-based vaccine plant in the United States, with nearly $500 million in subsidies from the US government. While these efforts may decrease the chance of dangerous supply shocks, in-fluenza countermeasure supply and production problems, as well as current concerns for other pharmaceutical products, are early warnings of a larger supply chain issue in MCMs and other crucial therapeutics with major implications for public health and national security.

Original languageEnglish (US)
Pages (from-to)255-257
Number of pages3
JournalBiosecurity and Bioterrorism
Volume10
Issue number3
DOIs
StatePublished - Sep 1 2012

Fingerprint

Security Measures
national security
Internationality
National security
Illicium
vaccine
globalization
Vaccines
influenza
drug
Influenza Vaccines
supply
Strategic Stockpile
medication
Shikimic Acid
Government Financing
security threat
Pharmaceutical Preparations
pharmaceutical
Drug products

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Health(social science)
  • Management, Monitoring, Policy and Law

Cite this

The globalization of US medical countermeasure production and its implications for national security. / Adalja, Amesh A.; Wollner, Samuel B.; Inglesby, Thomas V.; Poste, George.

In: Biosecurity and Bioterrorism, Vol. 10, No. 3, 01.09.2012, p. 255-257.

Research output: Contribution to journalArticle

Adalja, Amesh A. ; Wollner, Samuel B. ; Inglesby, Thomas V. ; Poste, George. / The globalization of US medical countermeasure production and its implications for national security. In: Biosecurity and Bioterrorism. 2012 ; Vol. 10, No. 3. pp. 255-257.
@article{99dc333c507d4143acf956155b74b5a3,
title = "The globalization of US medical countermeasure production and its implications for national security",
abstract = "Recent cases of counterfeit and contaminated medications have raised concerns about the integrity of the US supply chain of pharmaceuticals. Moreover, shortages in oncology drugs have highlighted a weak domestic production capacity for essential medications. The FDA and the Pew Charitable Trusts have published analyses of the problems as they relate to the US's regulatory system and healthcare industry.1,2 These issues also represent a potential national security threat. In preparing for and responding to pandemic influenza, US officials realized that a lack of domestic production capacity for flu vaccines and therapeutics heightened political tensions and shook popular confidence when these products became scarce. In 2005, Roche struggled to meet demand for oseltamivir because of a bad harvest of the star anise plant. Star anise is the source of shikimic acid, the backbone of the medication, and grows almost exclusively in 5 provinces of China. As a buffer against future shortages, 50 million doses were acquired for the Strategic National Stockpile (SNS), the federal repository of medical countermeasures (MCMs), to be used in a national emergency. In 2011, to augment domestic influenza vaccine production capacity, Novartis opened the first cell-based vaccine plant in the United States, with nearly $500 million in subsidies from the US government. While these efforts may decrease the chance of dangerous supply shocks, in-fluenza countermeasure supply and production problems, as well as current concerns for other pharmaceutical products, are early warnings of a larger supply chain issue in MCMs and other crucial therapeutics with major implications for public health and national security.",
author = "Adalja, {Amesh A.} and Wollner, {Samuel B.} and Inglesby, {Thomas V.} and George Poste",
year = "2012",
month = "9",
day = "1",
doi = "10.1089/bsp.2012.0622",
language = "English (US)",
volume = "10",
pages = "255--257",
journal = "Health security",
issn = "2326-5094",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - The globalization of US medical countermeasure production and its implications for national security

AU - Adalja, Amesh A.

AU - Wollner, Samuel B.

AU - Inglesby, Thomas V.

AU - Poste, George

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Recent cases of counterfeit and contaminated medications have raised concerns about the integrity of the US supply chain of pharmaceuticals. Moreover, shortages in oncology drugs have highlighted a weak domestic production capacity for essential medications. The FDA and the Pew Charitable Trusts have published analyses of the problems as they relate to the US's regulatory system and healthcare industry.1,2 These issues also represent a potential national security threat. In preparing for and responding to pandemic influenza, US officials realized that a lack of domestic production capacity for flu vaccines and therapeutics heightened political tensions and shook popular confidence when these products became scarce. In 2005, Roche struggled to meet demand for oseltamivir because of a bad harvest of the star anise plant. Star anise is the source of shikimic acid, the backbone of the medication, and grows almost exclusively in 5 provinces of China. As a buffer against future shortages, 50 million doses were acquired for the Strategic National Stockpile (SNS), the federal repository of medical countermeasures (MCMs), to be used in a national emergency. In 2011, to augment domestic influenza vaccine production capacity, Novartis opened the first cell-based vaccine plant in the United States, with nearly $500 million in subsidies from the US government. While these efforts may decrease the chance of dangerous supply shocks, in-fluenza countermeasure supply and production problems, as well as current concerns for other pharmaceutical products, are early warnings of a larger supply chain issue in MCMs and other crucial therapeutics with major implications for public health and national security.

AB - Recent cases of counterfeit and contaminated medications have raised concerns about the integrity of the US supply chain of pharmaceuticals. Moreover, shortages in oncology drugs have highlighted a weak domestic production capacity for essential medications. The FDA and the Pew Charitable Trusts have published analyses of the problems as they relate to the US's regulatory system and healthcare industry.1,2 These issues also represent a potential national security threat. In preparing for and responding to pandemic influenza, US officials realized that a lack of domestic production capacity for flu vaccines and therapeutics heightened political tensions and shook popular confidence when these products became scarce. In 2005, Roche struggled to meet demand for oseltamivir because of a bad harvest of the star anise plant. Star anise is the source of shikimic acid, the backbone of the medication, and grows almost exclusively in 5 provinces of China. As a buffer against future shortages, 50 million doses were acquired for the Strategic National Stockpile (SNS), the federal repository of medical countermeasures (MCMs), to be used in a national emergency. In 2011, to augment domestic influenza vaccine production capacity, Novartis opened the first cell-based vaccine plant in the United States, with nearly $500 million in subsidies from the US government. While these efforts may decrease the chance of dangerous supply shocks, in-fluenza countermeasure supply and production problems, as well as current concerns for other pharmaceutical products, are early warnings of a larger supply chain issue in MCMs and other crucial therapeutics with major implications for public health and national security.

UR - http://www.scopus.com/inward/record.url?scp=84866267938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866267938&partnerID=8YFLogxK

U2 - 10.1089/bsp.2012.0622

DO - 10.1089/bsp.2012.0622

M3 - Article

C2 - 22788798

AN - SCOPUS:84866267938

VL - 10

SP - 255

EP - 257

JO - Health security

JF - Health security

SN - 2326-5094

IS - 3

ER -